Precision medicine in Type 2 Diabetes: Targeting SGLT2-inhibitor Treatment For Kidney Protection

Thijs T Jansz, Katherine G Young, Rhian Hopkins, Andrew P McGovern, Beverley M Shields, Andrew T Hattersley, Angus G Jones, Ewan R Pearson, Richard A Oram, John M Dennis, MASTERMIND Consortium
{"title":"Precision medicine in Type 2 Diabetes: Targeting SGLT2-inhibitor Treatment For Kidney Protection","authors":"Thijs T Jansz, Katherine G Young, Rhian Hopkins, Andrew P McGovern, Beverley M Shields, Andrew T Hattersley, Angus G Jones, Ewan R Pearson, Richard A Oram, John M Dennis, MASTERMIND Consortium","doi":"10.1101/2024.09.01.24312905","DOIUrl":null,"url":null,"abstract":"<strong>Background</strong> Current guidelines recommend sodium-glucose cotransporter-2 inhibitors (SGLT2i) for kidney protection to a broad range of people with type 2 diabetes (T2D), but many were not represented in key kidney outcome trials and have unclear benefit. We aimed to identify which of these people are likely to benefit.","PeriodicalId":501419,"journal":{"name":"medRxiv - Endocrinology","volume":"1 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-09-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"medRxiv - Endocrinology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1101/2024.09.01.24312905","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Background Current guidelines recommend sodium-glucose cotransporter-2 inhibitors (SGLT2i) for kidney protection to a broad range of people with type 2 diabetes (T2D), but many were not represented in key kidney outcome trials and have unclear benefit. We aimed to identify which of these people are likely to benefit.
2 型糖尿病的精准医疗:瞄准 SGLT2 抑制剂治疗以保护肾脏
背景 目前的指南推荐钠-葡萄糖共转运体-2抑制剂(SGLT2i)为广大2型糖尿病(T2D)患者提供肾脏保护,但许多患者在关键的肾脏结果试验中并不具有代表性,其获益也不明确。我们的目标是确定这些人中哪些可能受益。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信